Abstract：
Sinonasal tumors are rare and heterogeneous diseases which pose challenges in diagnosis and treatment. Despite significant progress made in surgical, oncological, and radiotherapy fields, their prognosis still remains poor. Therefore, alternative strategies should be studied in order to refine diagnosis and improve patient care.
In recent years, in-depth molecular studies have identified new biological markers, such as genetic abnormalities and epigenetic variations, which have allowed to refine diagnosis and predict prognosis. As a consequence, new histological entities have been described and specific subgroup stratifications within the well-known histotypes have been made possible. These discoveries have expanded indications for immunotherapy and targeted therapies in order to reduce tumor spread, thus representing a valuable implementation of standard treatments. Recent findings in molecular biology have paved the way for better understanding and managing such rare and aggressive tumors. Although further efforts need to be made in this direction, expectations are promising.
In recent years, in-depth molecular studies have identified new biological markers, such as genetic abnormalities and epigenetic variations, which have allowed to refine diagnosis and predict prognosis. As a consequence, new histological entities have been described and specific subgroup stratifications within the well-known histotypes have been made possible. These discoveries have expanded indications for immunotherapy and targeted therapies in order to reduce tumor spread, thus representing a valuable implementation of standard treatments. Recent findings in molecular biology have paved the way for better understanding and managing such rare and aggressive tumors. Although further efforts need to be made in this direction, expectations are promising.
摘要：
鼻腔鼻窦肿瘤是一种罕见且异质性的疾病，对诊断和治疗提出了挑战。尽管在外科手术方面取得了重大进展，肿瘤学，和放射治疗领域，他们的预后仍然很差。因此,应研究替代策略,以完善诊断和改善患者护理.
近年来,深入的分子研究已经确定了新的生物标记，如遗传异常和表观遗传变异，这使得可以完善诊断和预测预后。因此,已经描述了新的组织学实体，并且已经使众所周知的组织学中的特定亚组分层成为可能。这些发现扩大了免疫治疗和靶向治疗的适应症，以减少肿瘤扩散。因此代表了标准治疗的有价值的实施。分子生物学的最新发现为更好地理解和管理这种罕见和侵袭性肿瘤铺平了道路。尽管在这方面还需要进一步努力,期望是有希望的。
近年来,深入的分子研究已经确定了新的生物标记，如遗传异常和表观遗传变异，这使得可以完善诊断和预测预后。因此,已经描述了新的组织学实体，并且已经使众所周知的组织学中的特定亚组分层成为可能。这些发现扩大了免疫治疗和靶向治疗的适应症，以减少肿瘤扩散。因此代表了标准治疗的有价值的实施。分子生物学的最新发现为更好地理解和管理这种罕见和侵袭性肿瘤铺平了道路。尽管在这方面还需要进一步努力,期望是有希望的。
